Intravenous Infusions is trading at GHS 0.70, up 7.69%, with no reliable company-specific announcement dated August 26, 2026 found to explain the move.
- The latest notable company news was an August 4, 2026 report on a return to profitability and planned equity funding, but it does not directly establish today’s catalyst.
- Broader U.S. indices were mixed and below the threshold for a strong global-market explanation.